A clinical trial involving 519 men found that a new oral medication utilizing extended-release minoxidil resulted in hair growth four times higher than that of a placebo group, according to study results. The drug is being positioned as one of the most significant advancements in baldness treatment in decades.
- Participant Pool: 519 men participated in the clinical trial.
- Primary Result: Hair growth was four times greater in the treatment group than in the placebo group.
- Delivery Method: An oral pill using an extended-release version of minoxidil.
How extended-release minoxidil differs from current treatments
The medication uses minoxidil, a known vasodilator used for years in topical foams and liquids to treat hair loss. However, this new version is an oral pill designed with an extended-release mechanism, which allows the drug to be absorbed into the bloodstream more slowly and consistently over time, according to the research data.
By moving the treatment from a topical application to an oral dose, the medication eliminates the need for daily scalp application, which often presents a barrier to patient compliance.
What the clinical trial data shows
The trial focused on men experiencing hair loss, with 519 participants enrolled to test the efficacy of the oral formula. According to the study authors, the results showed a stark contrast between those receiving the drug and those receiving a placebo, with the active treatment group demonstrating hair growth four times higher than the control group.
Researchers describe these results as promising, noting that the oral delivery system achieved a level of regrowth that marks a substantial shift in how androgenetic alopecia can be managed.
When the medication may become available
While the trial results are positive, the drug is not yet available for general prescription. According to reports on the study, there is now high expectation regarding the timeline for regulatory approval and market arrival.
The study establishes the efficacy of the extended-release formula, but further details regarding long-term safety profiles and final regulatory filing dates have not been specified in the current findings.
